Table 2.

Characteristics of CPG for the diagnosis and management of RVO.

Characteristic	Sub-characteristic	RCO	EURETINA	PPP	SERV	CEC
Guideline status		Update	New	Update	Update	New
Developer organization		Society	Society	Society	Society	Private
Funding		NR	NR	Yes	NR	Novartis Pharmaceuticals Canada
Development group	Number	5	8	7	8	11
	Affiliation details	Yes	Yes	No	Yes	Yes.
	Specialty/sub-specialty details	No	No	No	No	No
	Non-physician specialist	No	No	No	No	No
	Haematologist	Yes	No	No	No	No
	Population representative	No	No	No	No	No
	Methodologist	No	No	Yes	No	No
External review		NR	NR	Yes	Yes	NR
General features	Objective	Yes	NO	Yes	Yes	No
	Scope	Yes	No	Yes	No	No
	Target users	Yes	No	Yes	No	Yes
	Population	Yes	No	Yes	No	Yes
Evidence search	Search strategy	Yes	No	Yes	No	No
	Number of referenced citations	140	158	111	174	117
Update	Previous guide	2015	NA	2015 (2021a)	2010	NA
	Next update	2025	NA	2024	NR	NA
Detailed declaration of conflict of interest		Yes	Yes	Yes	Yes	No
Monitoring and/or auditing criteria		Yes	No	No	No	No
Evidence and grading of recommendations		NR	NR	Level of evidence: SIGN Recommendation: GRADE	US Agency for Health Research and Quality	Own level of evidence system

NR not reported, NA not applicable, RCO Royal College of Ophthalmologists, EURETINA European Society of Retina Specialists, PPP Preferred Practice Pattern, SERV Sociedad Española de Retina y Vítreo, CEC Canadian Expert Consensus.

^aAvailable at SERV website (only for SERV member) report: ‘Last modification: 17/09/2021’.